Search results
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own...
Simply Wall St. via Yahoo Finance· 10 months agoKey Insights Significant control over Lexicon Pharmaceuticals by private equity firms implies that...
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48%...
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Lexicon Pharmaceuticals' significant private equity firms ownership suggests that the...
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out...
Zacks via Yahoo Finance· 3 months agoLexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely...
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
Zacks via Yahoo Finance· 1 year agoLexicon’s LXRX shares were up almost 18% on May 26, after market hours. The rise was due to the FDA...
Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoLexicon Pharmaceuticals (NASDAQ:LXRX) Third Quarter 2022 ResultsKey Financial Results Net loss:...
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 3 months agoLexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 months agoLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript November 8, 2023...
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Zacks via Yahoo Finance· 3 months agoNew post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic...
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Benzinga via Yahoo Finance· 2 years agoLexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial...
Independent Chairman of the Board of Lexicon Pharmaceuticals Picks Up 293% More Stock
Simply Wall St. via Yahoo Finance· 8 months agoThose following along with Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will no doubt be intrigued by...